Back to UBS Group AG UBS Group AG

IKTIKT
12 quarters

Position history for UBS Group AGUBS Group AG's holdings in INHIBIKASE THERAPEUTICS INC

UBS Group AG holds 204,654 shares of IKT (INHIBIKASE THERAPEUTICS INC), worth $415,448 as of 2026-Q2. The position was decreased (-10.3% shares). IKT represents 0.0% of UBS Group AG's portfolio.

Current Value

$415,448

Current Shares

204,654

Total Value Change

+$415,241

Total Shares Change

+204,505

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
204,654
-10.3%
$415,4480.0%$2.03
0
2026-Q1
Increased
228,151
+141.3%
$383,2930.0%$1.91
38
2025-Q4
Decreased
94,545
-30.6%
$193,8170.0%$1.97
0
2025-Q3
Increased
136,280
+252.4%
$220,7730.0%$1.53
25
2025-Q2
Decreased
38,674
-14.6%
$75,4140.0%$1.62
0
2025-Q1
Increased
45,266
+64.5%
$99,1330.0%$2.29
22
2024-Q4
Increased
27,526
+464.9%
$89,4600.0%$3.24
24
2024-Q3
New
4,873
-
$6,3350.0%$1.17
24
2024-Q2
Exited
0
-100.0%
$00.0%$1.21
0
2024-Q1
New
3,214
-
$6,9420.0%$2.16
25
2023-Q4
Exited
0
-100.0%
$00.0%$1.27
0
2023-Q3
New
149
-
$2070.0%$1.39
17

Other major holders of IKT: BlackRock, Inc., Blackstone Inc., VANGUARD CAPITAL MANAGEMENT LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used